(6-hydroxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-acetic acid methyl ester | 212572-53-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 四氢化萘
• 英文名称: (6-hydroxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-acetic acid methyl ester
• 英文别名: methyl 2-(6-hydroxy-1,2,3,4-tetrahydronaphthalen-2-yl)acetate
• CAS: 212572-53-7
• 化学式: C₁₃H₁₆O₃
• 分子量: 220.268
• InChiKey: AFYWWBJQRXAUEQ-UHFFFAOYSA-N

物化性质

• 沸点：
  357.2±35.0 °C(Predicted)
• 密度：
  1.145±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (6-hydroxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-acetic acid methyl ester 在 苄基三甲基氢氧化铵 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 4.0h， 生成 methyl 2-[6-[[4-[N'-[(2-methylpropan-2-yl)oxycarbonyl]carbamimidoyl]phenyl]methoxy]-1,2,3,4-tetrahydronaphthalen-2-yl]acetate
  参考文献：
  名称：

  Fused Bicyclic Gly-Asp β-Turn Mimics with Specific Affinity for GPIIb-IIIa

  摘要：

  Disubstituted isoquinolones 2 and 3 have affinity for GPIIb-IIIa and represent leads for further structural evaluation. Structure-activity studies centered on the bicyclic beta-turn mimic contained in these molecules indicated that this moiety could accommodate a variety of modifications. Specifically, monocyclic, 6,5-bicyclic, and 6,7-bicyclic structures provide compounds with affinity for GPIIb-IIIa. Within the 6,6-series, isoquinoline, tetralin, tetralone, and benzopyran nuclei yield potent antagonists that are specific for GPIIb-IIIa. Attachment of the arginine isostere (benzamidine) to the supporting nucleus can be accomplished with an ether or amide linkage, although the latter enhances activity. Several compounds in this series provided measurable blood levels after oral dosing. Conversion of the acid moiety in these molecules to an ester generally provided compounds which gave greater systemic exposure after oral administration. Absolute bioavailabilities in the rat for the ethyl ester prodrug derivatives of the tetralin, tetralone, and benzopyran analogues of 3 were 28%, 23%, and 24%, respectively.

  DOI：

  10.1021/jm990365y
• 作为产物：
  描述：

  6-甲氧基-3,4-二氢-1H-2-萘酮 在 palladium on activated charcoal 氢气 、 三溴化硼 、 sodium hydride 作用下， 生成 (6-hydroxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-acetic acid methyl ester
  参考文献：
  名称：

  Fused Bicyclic Gly-Asp β-Turn Mimics with Specific Affinity for GPIIb-IIIa

  摘要：

  Disubstituted isoquinolones 2 and 3 have affinity for GPIIb-IIIa and represent leads for further structural evaluation. Structure-activity studies centered on the bicyclic beta-turn mimic contained in these molecules indicated that this moiety could accommodate a variety of modifications. Specifically, monocyclic, 6,5-bicyclic, and 6,7-bicyclic structures provide compounds with affinity for GPIIb-IIIa. Within the 6,6-series, isoquinoline, tetralin, tetralone, and benzopyran nuclei yield potent antagonists that are specific for GPIIb-IIIa. Attachment of the arginine isostere (benzamidine) to the supporting nucleus can be accomplished with an ether or amide linkage, although the latter enhances activity. Several compounds in this series provided measurable blood levels after oral dosing. Conversion of the acid moiety in these molecules to an ester generally provided compounds which gave greater systemic exposure after oral administration. Absolute bioavailabilities in the rat for the ethyl ester prodrug derivatives of the tetralin, tetralone, and benzopyran analogues of 3 were 28%, 23%, and 24%, respectively.

  DOI：

  10.1021/jm990365y

文献信息

• Bicyclic antagonists selective for the &agr;v&bgr;3 integrin
  申请人：Wyeth

  公开号：US06429214B1

  公开（公告）日：2002-08-06

  This invention provides novel bicyclic compounds of Formula (I): wherein u, v, m, Y, G, A—B, R1, R1a, R2, R4, R5, R5a, and R5b are defined in the specification which compounds exhibit activity as inhibitors of bone resorption and compounds of Formula (II) wherein u, v, m, Y, G, D, A—B, R1, R1a, R2, R3, R4, R5, R5a, and R5b are defined in the specification which compounds exhibit activity as inhibitors of bone resorption.

  这项发明提供了式（I）的新颖双环化合物：其中u、v、m、Y、G、A—B、R1、R1a、R2、R4、R5、R5a和R5b在规范中定义，这些化合物表现出作为骨吸收抑制剂的活性；以及式（II）的化合物：其中u、v、m、Y、G、D、A—B、R1、R1a、R2、R3、R4、R5、R5a和R5b在规范中定义，这些化合物表现出作为骨吸收抑制剂的活性。
• Bicyclic antagonists selective for the alphavbeta3 integrin
  申请人：Wyeth

  公开号：US20030109523A1

  公开（公告）日：2003-06-12

  This invention provides novel bicyclic compounds of Formula (I): 1 wherein u, v, m, Y, G, A-B, R 1 , R 1a , R 2 , R 4 , R 5 , R 5a , and R 5b are defined in the specification which compounds exhibit activity as inhibitors of bone resorption and compounds of Formula (II) 2 wherein u, v, m, Y, G, D, A-B, R 1 , R 1a , R 2 , R 3 R 4 , R 5 , R 5a , and R 5b are defined in the specification which compounds exhibit activity as inhibitors of bone resorption.

  这项发明提供了公式（I）的新型双环化合物：其中u、v、m、Y、G、A-B、R1、R1a、R2、R4、R5、R5a和R5b在规范中有定义，这些化合物表现出抑制骨吸收的活性，以及公式（II）的化合物：其中u、v、m、Y、G、D、A-B、R1、R1a、R2、R3、R4、R5、R5a和R5b在规范中有定义，这些化合物也表现出抑制骨吸收的活性。
• ARYL GPR120 RECEPTOR AGONISTS AND USES THEREOF
  申请人：Ma Jingyuan

  公开号：US20100216827A1

  公开（公告）日：2010-08-26

  Aryl GPR120 agonists are provided. These compounds are useful for the treatment of metabolic diseases, including Type II diabetes and diseases associated with poor glycemic control.

  提供了芳基GPR120激动剂。这些化合物对于治疗代谢性疾病，包括II型糖尿病和与糖代谢控制不良有关的疾病非常有用。
• Aryl gpr120 receptor agonists and uses thereof
  申请人：Camabay Therapeutics, Inc.

  公开号：EP2690095A1

  公开（公告）日：2014-01-29

  Aryl GPR120 agonists are provided. These compounds are useful for the treatment of metabolic diseases, including Type II diabetes and diseases associated with poor glycemic control.

  提供了芳基 GPR120 激动剂。这些化合物可用于治疗代谢性疾病，包括 II 型糖尿病和与血糖控制不良有关的疾病。
• [EN] ARYL GPR120 RECEPTOR AGONISTS AND USES THEREOF<br/>[FR] AGONISTES DE RÉCEPTEUR GPR120 ARYL ET UTILISATIONS DE CEUX-CI
  申请人：METABOLEX INC

  公开号：WO2010048207A3

  公开（公告）日：2010-06-17